# A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

> **NCT02737072** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 9 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** LY2510924
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT02737072
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2017-09-25
- **Final completion:** 2017-09-25
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02737072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02737072, "A Study of LY2510924 and Durvalumab in Participants With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02737072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*